MINORYX THERAPEUTICS
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.
MINORYX THERAPEUTICS
Social Links:
Industry:
Biotechnology Genetics Medical Pharmaceutical
Founded:
2011-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.minoryx.com
Total Employee:
11+
Status:
Active
Contact:
34 93 702 19 75
Email Addresses:
[email protected]
Total Funding:
143.91 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Ysios Capital
Ysios Capital investment in Series C - Minoryx Therapeutics
Centre for the Development of Industrial Technology (CDTI)
Centre for the Development of Industrial Technology (CDTI) investment in Series C - Minoryx Therapeutics
Caixa Capital Risc
Caixa Capital Risc investment in Series C - Minoryx Therapeutics
Fund+
Fund+ investment in Series C - Minoryx Therapeutics
Columbus Venture Partners
Columbus Venture Partners investment in Series C - Minoryx Therapeutics
European Investment Bank
European Investment Bank investment in Debt Financing - Minoryx Therapeutics
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Minoryx Therapeutics
Kurma Partners
Kurma Partners investment in Series B - Minoryx Therapeutics
Fund+
Fund+ investment in Series B - Minoryx Therapeutics
S.R.I.W.
S.R.I.W. investment in Series B - Minoryx Therapeutics
Official Site Inspections
http://www.minoryx.com
- Host name: 87.106.237.121
- IP address: 87.106.237.121
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Minoryx Therapeutics"
Minoryx official website
At Minoryx, we are committed to making innovative treatments available for patients suffering from life threatening orphan diseases. Minoryx is focused on the discovery and development of …See details»
Board of Directors - Minoryx
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high unmet medical need.See details»
Minoryx is a clinical stage biotech company
Minoryx is a clinical-stage biotech company focused on the discovery and development of novel therapies for severe, orphan genetic diseases of the central nervous system (CNS) with high unmet medical need.See details»
Minoryx Therapeutics S.L. - Devex
Minoryx is a clinical-stage biotech company focused on the discovery and development of novel therapies for severe, orphan genetic diseases of the central nervous system (CNS) with high...See details»
Minoryx Therapeutics - Crunchbase Company Profile & Funding
Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases. View contacts for Minoryx Therapeutics to access new …See details»
Minoryx Company Profile 2024: Valuation, Funding & Investors
Operator of a biotechnology platform intended to provide treatments for life-threatening rare diseases.See details»
Minoryx | VentureRadar
Website: http://www.minoryx.com/ Develops novel PPAR gamma agonists targeting orphan CNS disorders, with leriglitazone showing promise in treating X-ALD and Friedreich's Ataxia. …See details»
Minoryx Therapeutics - The Org
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases.See details»
Spain: EIB provides Minoryx with up to €25 million to support ...
Oct 30, 2020 · The EIB today announced that it has approved €25 million financing for Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of …See details»
Minoryx Therapeutics receives FDA Orphan Drug Designation for ...
Oct 17, 2019 · Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead …See details»
Minoryx announces enrollment of first patients with cerebral ...
Minoryx are currently conducting an extensive pre-screening campaign to identify eligible adults with cALD to take part in phase 3 of their clinical trial. The findings from the trials will enable …See details»
Minoryx Raises $55 Million to Support MAA and Launch for X-ALD …
May 31, 2022 · Spanish rare CNS disease focused biotech Minoryx Therapeutics raised $55 million (€51 million) to finance the marketing authorization application and launch preparations …See details»
Minoryx science approach
Minoryx focuses on orphan diseases of the central nervous system (CNS), a large group of rare diseases often characterized by neurodegeneration.See details»
Minoryx Q&A: incentivising orphan drug development
Nov 1, 2021 · Minoryx CEO Marc Martinell discusses the challenges of orphan drug development, and how companies can be incentivised to enter the market.See details»
Minoryx raises EUR 51 million to support Marketing Authorization ...
May 31, 2022 · Minoryx Therapeutics, a Phase 3 stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today …See details»
Minoryx pipeline overview
Minoryx’s lead program is a selective, differentiated PPAR gamma agonist (leriglitazone) under development for the treatment of X-linked Adrenoleukodystrophy (X-ALD); it has the potential …See details»
Kelly Miettunen Executive Director, ALD connect
Oct 11, 2021 · On behalf of Minoryx Therapeutics I would like to provide you an overview on the recent interruption of dosing with leriglitazone on patients participating at the Advance Open …See details»
European Investment Bank provides Minoryx with up to €25 …
Announces that the European Investment Bank (EIB) has approved a €25 million nondilutive financing. The EU bank will grant long-term financing to Minoryx to drive the company’s …See details»
Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant …
2 days ago · Nuak1 (NUAK family SnF1-like kinase-1) is a serine-threonine kinase and a member of the AMPK family. Interest in Nuak1 has increased over the years due to the role it plays in …See details»
Minoryx publishes mechanism of action of leriglitazone in X-ALD …
Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, …See details»